UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pseudoprogression and Immune-Related Response in Solid Tumors

Journal of clinical oncology, 2015-11, Vol.33 (31), p.3541-3543

2015

Volltextzugriff (PDF)

The MAPK pathway across different malignancies: A new perspective

Cancer, 2014-11, Vol.120 (22), p.3446-3456

2014

Volltextzugriff (PDF)

Reply to A. Wong et al

Journal of clinical oncology, 2016-05, Vol.34 (13), p.1562-1563

2016

Volltextzugriff (PDF)

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Clinical cancer research, 2017-03, Vol.23 (6), p.1397-1406

2017

Volltextzugriff (PDF)

Diversity of US participants in AstraZeneca-sponsored clinical trials

Contemporary clinical trials, 2024-05, Vol.140, p.107496, Article 107496

2024

Volltextzugriff (PDF)

Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction

Brain research, 2011-01, Vol.1368 (12), p.290-298

2011

Volltextzugriff (PDF)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

Oncotarget, 2017-10, Vol.8 (45), p.79175-79187

2017

Volltextzugriff (PDF)

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

Oncotarget, 2019-04, Vol.10 (30), p.2855-2868

2019

Volltextzugriff (PDF)

297 Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A324-A324

2020

Volltextzugriff (PDF)

Novel Therapeutic Strategies For Angiogenesis Inhibition In Recurrent Ovarian Cancer

Current Angiogenesis, 2015-08, Vol.3 (4), p.179-192

2015

Volltextzugriff (PDF)

Metabolic Programming of Hematopoietic Stem Cell Function By Prenatal Folate

Blood, 2023-11, Vol.142 (Supplement 1), p.5-5

2023

Volltextzugriff (PDF)

3107 – METABOLIC PROGRAMMING OF HEMATOPOIETIC STEM CELL FUNCTION BY PRENATAL FOLATE

Experimental hematology, 2023, Vol.124, p.S103

2023

Volltextzugriff (PDF)

Abstract CT126: A phase I first time in human study to evaluate the safety, pharmacokinetics, and immunogenicity of MEDI5083 alone and in combination with durvalumab in selected advanced solid tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT126-CT126

2018

Volltextzugriff (PDF)

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS11582-TPS11582

2021

Volltextzugriff (PDF)

A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3100-TPS3100

2017

Volltextzugriff (PDF)

Abstract CT326: Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women's cancers

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT326-CT326

2015

Volltextzugriff (PDF)

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5514-5514

2015

Volltextzugriff (PDF)

Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3015-3015

2016

Volltextzugriff (PDF)

Abstract CT337: Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT337-CT337

2014

Volltextzugriff (PDF)

A Single Institution Analysis of Incidence of Recurrent Chromosomal Abnormalities in Adult ALL Patients According to Race, Gender, and Age

Blood, 2011-11, Vol.118 (21), p.4869-4869

2011

Volltextzugriff (PDF)

Randomized controlled trial of a safer sex intervention for high-risk adolescent girls

Archives of pediatrics & adolescent medicine, 2001-01, Vol.155 (1), p.73

2001

Volltextzugriff (PDF)

William Carlos Williams Poetry Contest Winners

The Journal of medical humanities, 2007-12, Vol.28 (4), p.255-258

2007

Volltextzugriff (PDF)

Pragmatic solutions for optimizing oncology drug development trials

Reference Module in Biomedical Research, 2015

2015

Volltextzugriff (PDF)

A Qualitative, theory-based study of adolescent girls’ knowledge and attitudes about pap smears and compliance with follow-up

Journal of pediatric & adolescent gynecology, 1998-11, Vol.11 (4), p.209-209

1998

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(46)
Buchkapitel
(1)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pseudoprogression and Immune-Related Response in Solid Tumors

The MAPK pathway across different malignancies: A new perspective

Reply to A. Wong et al

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Diversity of US participants in AstraZeneca-sponsored clinical trials

Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

297 Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Novel Therapeutic Strategies For Angiogenesis Inhibition In Recurrent Ovarian Cancer

Metabolic Programming of Hematopoietic Stem Cell Function By Prenatal Folate

3107 – METABOLIC PROGRAMMING OF HEMATOPOIETIC STEM CELL FUNCTION BY PRENATAL FOLATE

Abstract CT126: A phase I first time in human study to evaluate the safety, pharmacokinetics, and immunogenicity of MEDI5083 alone and in combination with durvalumab in selected advanced solid tumors

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2)

Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a02 + previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO)

A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors

Abstract CT326: Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women's cancers

Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418)

Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404)

Abstract CT337: Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062)

A Single Institution Analysis of Incidence of Recurrent Chromosomal Abnormalities in Adult ALL Patients According to Race, Gender, and Age

Randomized controlled trial of a safer sex intervention for high-risk adolescent girls

William Carlos Williams Poetry Contest Winners

Pragmatic solutions for optimizing oncology drug development trials

A Qualitative, theory-based study of adolescent girls’ knowledge and attitudes about pap smears and compliance with follow-up

Suchergebnisse filtern